Effective December 19, 2018 Strongbridge sold the United States and Canadian rights to Macrilen™ (macimorelin) under the License and Assignment Agreement to Novo
2019
On January 16, 2019, the Company announced that the EMA granted marketing authorization
March 12, 2019 The Special Committee has approved the engagement by the Company of Torreya
September 24, 2019 : KE 3,325,000 Common Shares zu 1,5$ + 3,325,000 Warrants zu 1,65$ gezeichnet u.A. von Empery Asset Management, LP ( Event-Driven-Strategie Hedgefond)
16,632,410 Common Shares auf 19,957,410 Common Shares
2020 March 10, 2020 Ablauf Warrants March 2015 offering - Series A 28,144 1.07$
March 20, 2020 Die neuen Warrants können ausgeübt werden (3,325,000 Warrants zu 1,65)
May 1, 2020 Ablauf Warrants November 2016 offering 945,000 4.70$
Jun 2020 Max. ende Kohle ohne die neue KE bei 2,6 Mio Verlust pro Q
By July 2020 Date of completion: Study AEZS-130-P01 Teil 1 PIP
Okt-Nov 2020 14 Mio$ cash : Sollte im Q4 2020 verbraucht sein
December 13, 2020 Ablauf Warrants December 2015 offering 2,331,000 7.10$
2021
Apr-Mai Ende Kohle nach einer Ausübung der 1,65$ Warrants (neue KE)
2022 July 2022 Date of completion: Study AEZS-130-P02 Teil 2 PIP ( Upon approval by the U.S. Food and Drug Administration (“FDA”) of a pediatric indication for Macrilen™ (macimorelin), Aeterna Zentaris will receive a one-time milestone payment of US$5,000,000 from Strongbridge. )
2023
2024
September 20, 2024 Ablauf Warrants der neuen KE
|